As of September 30, 2025, cash and cash equivalents totaled $42.7 million. The Company believes that it has a cash runway into 2027.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on UNCY:
- Ten new option listings on November 5th
- Optimistic Buy Rating for Unicycive Therapeutics Driven by Promising Clinical Progress and Financial Stability
- Unicycive Therapeutics to present new OLC data at ASN Kidney Week 2025
- Unicycive Therapeutics price target raised to $22 from $9 at H.C. Wainwright
- Unicycive Therapeutics Updates FDA Application for OLC